Glen S. Germain
Impact in
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 7
- Cancer therapeutics and mechanisms 5
- Oncology 12
- Drug Transport and Resistance Mechanisms 6
- Colorectal Cancer Treatments and Studies 3
- Peptidase Inhibition and Analysis 2
- Co-authors
- Peter J. Houghton (12 shared papers)Franklin C. Harwood (7 shared papers)Michael B. Dilling (4 shared papers)Clinton F. Stewart (2 shared papers)John D. Schuetz (2 shared papers)Peter J. Houghton (6 shared papers)Lili Shu (2 shared papers)Elisabeth Buchdunger (1 shared paper)
- Journals
- Journal of Biological Chemistry (3 papers)Biochemical Pharmacology (3 papers)Molecular Pharmacology (2 papers)Biochemical and Biophysical Research Communications (2 papers)Cancer Research (2 papers)
- Partner nations
- United StatesIndiaNetherlands
In The Last Decade
Glen S. Germain
30 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 98
- Oncology 558
- Genetics 165
- Molecular Biology 986
- Hematology 142
- Biochemistry 78
Countries citing papers authored by Glen S. Germain
This map shows the geographic impact of Glen S. Germain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glen S. Germain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glen S. Germain more than expected).
Fields of papers citing papers by Glen S. Germain
This network shows the impact of papers produced by Glen S. Germain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glen S. Germain. The network helps show where Glen S. Germain may publish in the future.
Co-authors
The 25 scholars most cited alongside Glen S. Germain, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 264 | |
| 2 | Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. | 1999 | 257 |
| 3 | 2004 | 163 | |
| 4 | Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. | 1994 | 115 |
| 5 | Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. | 1997 | 107 |
| 6 | 2004 | 94 | |
| 7 | 2005 | 89 | |
| 8 | 2002 | 87 | |
| 9 | Production of renomedullary prostaglandins by renomedullary interstitial cells grown in tissue culture. | 1972 | 87 |
| 10 | Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. | 2003 | 64 |
| 11 | 1990 | 27 | |
| 12 | 1977 | 26 | |
| 13 | 1993 | 22 | |
| 14 | N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells. | 1990 | 21 |
| 15 | 1989 | 18 | |
| 16 | Morphological and molecular characterization of spontaneous myogenic differentiation in a human rhabdomyosarcoma cell line. | 1990 | 17 |
| 17 | 1973 | 16 | |
| 18 | Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage. | 1987 | 16 |
| 19 | Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells. | 1998 | 16 |
| 20 | 1994 | 15 |
About Glen S. Germain
Glen S. Germain is a scholar working on Molecular Biology, Oncology, Toxicology, Pathology and Forensic Medicine and Infectious Diseases, having authored 30 papers that have together received 1.6k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (7 papers), Drug Transport and Resistance Mechanisms (6 papers), Cancer therapeutics and mechanisms (5 papers), Bioactive Compounds and Antitumor Agents (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Genetic factors in colorectal cancer (3 papers), HIV/AIDS drug development and treatment (3 papers) and Peptidase Inhibition and Analysis (2 papers). The work is most often cited by research in Oncology (558 citations), Genetics (165 citations), Molecular Biology (986 citations), Hematology (142 citations) and Biochemistry (78 citations). Glen S. Germain has collaborated with scholars based in United States, India and Netherlands. Frequent co-authors include Peter J. Houghton, Franklin C. Harwood, Michael B. Dilling, Clinton F. Stewart, John D. Schuetz, Peter J. Houghton, Lili Shu, Elisabeth Buchdunger, Peter Traxler and John Easton. Their work appears in journals such as Journal of Biological Chemistry, Biochemical Pharmacology, Molecular Pharmacology, Biochemical and Biophysical Research Communications and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.